Genor Biopharma Holdings Limited announced that Mr. Yi Qingqing ("Mr. Yi") has tendered his resignation as (i) the chairman of the Board (the "Chairman"); and (ii) a non-executive Director due to his decision to devote more time on his other businesses, with effect from 2 November 2021. Upon Mr. Yi's resignation, Mr. Yi also resigned from his role as the chairman of the nomination committee of the Board (the "Nomination Committee"). Following the resignation of Mr. Yi, the Board further announces that Dr. Guo Feng ("Dr. Guo"), an existing executive Director and the chief executive officer of the Company (the "CEO"), is appointed as the Chairman and Dr. Lyu Dong ("Dr. Lyu") is appointed as a non-executive Director, both with effect from 2 November 2021. Dr. Guo, aged 51, is an existing executive Director and CEO of the Company. Dr. Lyu, aged 46, is currently the managing director of Zhuhai Gao Ling Equity Investment Management Co. Ltd. Following Mr. Yi's resignation as the Chairman and a non-executive Director, Mr. Yi also resigned from his role as the chairman of the Nomination Committee, (i) Mr. Chen Wen ("Mr. Chen"), an existing independent non-executive Director and a member of the Nomination Committee, is appointed as the chairman of the Nomination Committee; and (ii) Dr. Lyu, the newly appointed non-executive Director, is appointed as a member of the Nomination Committee, both with effect from 2 November 2021. Accordingly, the Nomination Committee comprises Mr. Chen as the chairman of the Nomination Committee, and Dr. Lyu and Mr. Fung Edwin as members of the Nomination Committee.